References

1. Lesher GY, Froelich EJ, Gruett MD, Bailey JH, Brundage RP (1962) 1,8-Naphthyridine Derivatives. A New Class of Chemotherapeutic Agents. J Med Pharm Chem 91: 1063-1065 [CrossRef] [Google Scholar] [PubMed]
2. Van Bambeke F, Michot JM, Van Eldere J, Tulkens PM (2005) Quinolones in 2005: an update. Clin Microbiol Infect 11: 256-280 [CrossRef] [Google Scholar] [PubMed]
3. Van Bambeke F (2014) Renaissance of antibiotics against difficult infections: Focus on oritavancin and new ketolides and quinolones. Ann Med 46: 512-529 [CrossRef] [Google Scholar] [PubMed]
4. Walsh CT, Wencewicz TA (2014) Prospects for new antibiotics: a moleculecentered perspective. J Antibiot (Tokyo) 67: 7-22 [CrossRef] [Google Scholar] [PubMed]
5. Wright DH, Brown GH, Peterson ML, Rotschafer JC (2000) Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 46: 669-683 [CrossRef] [Google Scholar] [PubMed]
6. Remy JM, Tow-Keogh CA, McConnell TS, Dalton JM, DeVito JA. (2012) Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother 67: 2814-2820 [CrossRef] [Google Scholar] [PubMed]
7. Lemaire S, Tulkens PM, Bambeke VF (2011) Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-Gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother 55: 649-658 [CrossRef] [Google Scholar] [PubMed]
8. O’Riordan W, Mehra P, Manos P, Kingsley J, Lawrence L et al. (2015) Arandomized phase 2 study comparing two doses of delafloxacin withtigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis 30: 67-73 [CrossRef] [Google Scholar] [PubMed]
9. Nilius AM, Shen LL, Hensey-Rudloff D, Almer LS, Beyer JM, et al. (2003) In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob. Agents Chemother 47: 3260-3269 [CrossRef] [Google Scholar] [PubMed]
10. Flamm RK, Rhomberg PR, Huband MD, Farrell DJ (2016) In vitro activity ofdelafloxacin tested against isolates of Streptococcus pneumoniae, Haemophilusinfluenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother 60: 6381-6385 [CrossRef] [Google Scholar] [PubMed]
11. Soge OO, Salipante SJ, No D, Duffy E, Roberts MC. (2016) In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae isolates and selection of gonococcal delafloxacin resistance. Antimicrob Agents Chemother 60: 3106-3111 [CrossRef] [Google Scholar] [PubMed]
12. Bauer J, Siala W, Tulkens PM, Van Bambeke F (2013) A combined pharmacodynamicquantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aures biofilms. Antimicrob Agents Chemother. 57: 2726–2737 [CrossRef] [Google Scholar] [PubMed]
13. Lepak AJ, Andes DR (2016) In vivo pharmacodynamic target assessment of delafloxacin against Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 60: 4764 -4769 [CrossRef] [Google Scholar] [PubMed]
14. Thabit AK, Crandon JL, Nicolau DP (2016) Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. International Journal of Antimicrobial Agents 48: 535-541 [CrossRef] [Google Scholar] [PubMed]
15. Hoover R, Lawrence L, Benedict M, Hunt T, Gunda S, Li D, Sun E, Cammarata S. In: A phase 1 open-label crossover study to determine the effect of food on the pharmacokinetics of a single dose of oral delafloxacin in healthy subjects. Proceedings of the 54th interscience conference of antimicrobial agents and chemotherapy, Washington, USA, September 5-9, 2014
16. Litwin JS, Benedict MS, Thorn MD, Lawrence LE, Cammarata SK, et al. (2015) A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother 59: 3469-3473 [CrossRef] [Google Scholar] [PubMed]
17. Kingsley J, Mehra P, Lawrence LE, Henry E, Duffy E, et al. (2016) A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother 71: 821-829 [CrossRef] [Google Scholar] [PubMed]
18. Bambeke VF. (2015) Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy. Future Microbiol. 10: 1111–1123 [CrossRef] [Google Scholar] [PubMed]